logo-loader
Tesco

Tesco has target price cut by Deutsche Bank after Kantar data

Deutsche Bank kept a ‘buy’ rating on Tesco but lowered its target price to 295p from 300p

Tesco
Deutsche Bank reduced its estimates for Tesco's pre-tax profit and revenue in fiscal years 2020-22

Deutsche Bank cut its target price on the shares of Tesco PLC (LON:TSCO) after industry data showed a slowdown in UK supermarket sales.

Kantar Worldpanel said the grocery market grew by 1.3% in the 12 weeks to May 19, compared to last year’s 2.7% when a heatwave, the Royal Wedding and FA Cup final boosted sales.

READ: Sainsbury's and Asda become joint second biggest UK supermarkets, Kantar reveals

Tesco maintained a market share of 27.3% in the period with flat sales.

Deutsche Bank kept a ‘buy’ rating on Tesco but lowered its target price to 295p from 300p. It also reduced its estimates for pre-tax profit and revenue for fiscal years 2020-22.

“Quarterly UK retail sales growth ex fuel has a 79% correlation to Kantar data, and while Kantar and Tesco's periods do not perfectly overlap, Kantar suggests that Tesco will report +0.2% retail growth for the first quarter of 2020, close to our expectations,” the bank said.

“We expect the group to report 0.4% sales growth ex fuel, with 0.7% like-for-like growth ex fuel.”

Quick facts: Tesco

Price: £2.20

Market: LSE
Market Cap: £21.52 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

6 hours, 51 minutes ago

2 min read